Ravulizumab: A Study Drug for Infants, Children, and Young Adults Ages 1 month to 18 years old with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT
Thrombotic Microangiopathy (TMA) is blood clots that form in the body from damaged cells. Hematopoietic stem cell transplant (HSCT) is when other cells are used from a persons body to create normal blood cells. Ravulizumab is a study drug to help infants, children, and young adults ages 1 month to 18 years old with this disease after having HSCT. Research is needed to learn if the drug is safe and effective. The information we gain may aid patients.
- All genders
- Under 18 years old
- Volunteers with special conditions
- In Person
Who can participate?
Gender: All genders
Age: Under 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
- Infants and children 1 month to 18 years old
- TMA diagnosis
- HSCT within the past 6 months at the time of participation
- Required vaccinations
- In-person at the University of Utah
- Bone marrow or stem cell transplant failure
- Mental health issue
- Participation in another study
- Pregnant or breastfeeding
Will I be paid for my time?